Concepedia

Author

Luzelena Caro

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

L Caro, L. Caro, Luzelena Caro

11

Publications

180

Citations

7

H-Index

16

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Medizinische Hochschule Hannover
LC

About

Luzelena Caro is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, hepatology, and hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

55

2

Hepatology

2

2

21

3

Cell Biology

1

1

34

4

Immunology

1

1

11

5

Pharmacology

1

1

10

Luzelena Caro

×

7

Publications

179

Citations

7

H-Index

YearCitations

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

Michael P. Manns, Edward Gane, M. Rodríguez‐Torres,

Hepatology

2012

57

Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults

Jia Yao Phuah, Brian M. Maas, Aimin Tang,

Biomedicine & Pharmacotherapy

2023

38

Lesion-induced expression of low-affinity nerve growth factor receptor-immunoreactive protein in Purkinje cells of the adult rat

Ricardo Martı́nez-Murillo, Luzelena Caro, Manuel Nieto‐Sampedro

Neuroscience

1993

34

[Evaluation of a pharmaceutical care program to improve adherence to antiretroviral therapy].

C. Codina Jané, M Tuset Creus, O Ibarra Barrueta,

PubMed

2004

15

Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients

D. Hamish Wright, Luzelena Caro, Michael Cerra,

Antiviral Therapy

2014

14

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

M.P. Manns, John M. Vierling, B. Bacon,

Journal of Hepatology

2013

11

803 RELATIONSHIP BETWEEN TRANSAMINASE LEVELS AND PLASMA PHARMACOKINETICS FOLLOWING ADMINISTRATION OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) TO HCV GENOTYPE (G) 1 TREATMENT-NAÏVE PATIENTS

Luzelena Caro, Lihong Du, Shenlin Huang,

Journal of Hepatology

2013

10

Page 1